華潤醫藥(03320.HK)擬收購博雅生物(300294.SZ)控股權
格隆匯 9 月 28日丨華潤醫藥(03320.HK)發佈公告,公司全資附屬公司華潤醫藥控股已與深圳市高特佳投資集團有限公司訂立有關建議收購事項的意向書。華潤醫藥控股擬收購博雅生物製藥集團股份有限公司的控股權,而建議收購事項的條款須待華潤醫藥控股與賣方進行進一步磋商後,方可作實。
目標公司博雅生物製藥集團股份有限公司(300294.SZ)在深圳證券交易所上市,從事生產醫藥產品業務。目標公司主要從事開發、生產及銷售血液製品、糖尿病藥物、抗感染化學藥品及生化藥品等其他產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.